Have a personal or library account? Click to login
Vitamin D and Hyperkinetic Movement Disorders: A Systematic Review Cover

Vitamin D and Hyperkinetic Movement Disorders: A Systematic Review

Tremor and Other Hyperkinetic Movements
Volume 10 (2020): Issue 0
By: Carl N. Homann,  Gerd Ivanic,  Barbara Homann and  Tadeja Urbanic Purkart  
Open Access
|Aug 2020

References

  1. 1Annweiler C, Schott AM, Berrut G, et al. Vitamin D and ageing: Neurological issues. Neuropsychobiology. 2010; 62: 139–50. DOI: 10.1159/000318570
    Back to article
  2. 2Rimmelzwaan LM, van Schoor NM, Lips P, et al. Systematic Review of the Relationship between Vitamin D and Parkinson’s Disease. J Parkinsons Dis. 2016; 6: 29–37. DOI: 10.3233/JPD-150615
    Back to article
  3. 3Torsney KM, Noyce AJ, Doherty KM, et al. Bone health in Parkinson’s disease: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014; 85: 1159–66. DOI: 10.1136/jnnp-2013-307307
    Back to article
  4. 4Lyell V, Henderson E, Devine M, et al. Assessment and management of fracture risk in patients with Parkinson’s disease. Age Ageing. 2015; 44: 34–41. DOI: 10.1093/ageing/afu122
    Back to article
  5. 5Peterson AL, Murchison C, Zabetian C, et al. Memory, mood, and vitamin D in persons with Parkinson’s disease. J Parkinsons Dis. 2013; 3: 547–55. DOI: 10.3233/JPD-130206
    Back to article
  6. 6Grimbergen YAM, Knol MJ, Bloem BR, et al. Falls and gait disturbances in Huntington’s disease. Mov Disord. 2008; 23: 970–976. DOI: 10.1002/mds.22003
    Back to article
  7. 7Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord. 2007; 22: 1743–50. DOI: 10.1002/mds.21599
    Back to article
  8. 8Wheelock VL, Tempkin T, Marder K, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003; 60: 998–1001. DOI: 10.1212/01.WNL.0000052992.58107.67
    Back to article
  9. 9Chel VG, Ooms ME, van der Bent J, et al. High prevalence of vitamin D deficiency and insufficiency in patients with manifest Huntington disease: An explorative study. Dermatoendocrinol. 2013; 5: 348–51. DOI: 10.4161/derm.26135
    Back to article
  10. 10Costa de Miranda R, Di Lorenzo N, Andreoli A, et al. Body composition and bone mineral density in Huntington’s disease. Nutrition. 2018; 59: 145–149. DOI: 10.1016/j.nut.2018.08.005
    Back to article
  11. 11Goodman AO, Barker RA. Body composition in premanifest Huntington’s disease reveals lower bone density compared to controls. PLoS Curr. 2011; 3: RRN1214. DOI: 10.1371/currents.RRN1214
    Back to article
  12. 12Bonelli CM, Bonelli R, Eichinger M, et al. Bone density and bone turnover in Huntington’s disease; 2002.
    Back to article
  13. 13Otti DV, Hödl AK, Bonelli CM, et al. Osteoporosis in Huntington’s disease The world journal of biological psychiatry. 2002; 8: 23.
    Back to article
  14. 14Busse ME, Wiles CM, Rosser AE. Mobility and falls in people with Huntington’s disease. J Neurol Neurosurg Psychiatry. 2009; 80: 88–90. DOI: 10.1136/jnnp.2008.147793
    Back to article
  15. 15Alsafadi S, Abaalkhail B, Wali SO, et al. Risk factors of primary and secondary restless legs syndrome among a middle-aged population in Saudi Arabia: A community-based study. Ann Thorac Med. 2018; 13: 175–181. DOI: 10.4103/atm.ATM_344_17
    Back to article
  16. 16Balaban H, Yildiz OK, Cil G, et al. Serum 25-hydroxyvitamin D levels in restless legs syndrome patients. Sleep Med. 2012; 13: 953–7. DOI: 10.1016/j.sleep.2012.04.009
    Back to article
  17. 17Schilling C, Schredl M, Strobl P, et al. Restless legs syndrome: evidence for nocturnal hypothalamic-pituitary-adrenal system activation. Mov Disord. 2010; 25: 1047–52. DOI: 10.1002/mds.23026
    Back to article
  18. 18Cikrikcioglu MA, Halac G, Hursitoglu M, et al. Prevalence of gluten sensitive enteropathy antibodies in restless legs syndrome. Acta Neurol Belg. 2011; 111: 282–6.
    Back to article
  19. 19Kuzniar TJ, Silber MH. Multiple skeletal injuries resulting from uncontrolled restless legs syndrome. J Clin Sleep Med. 2007; 3: 60–1.
    Back to article
  20. 20Wali S, Shukr A, Boudal A, et al. The effect of vitamin D supplements on the severity of restless legs syndrome. Sleep Breath. 2015; 19: 579–83. DOI: 10.1007/s11325-014-1049-y
    Back to article
  21. 21Wali SO, Abaalkhail B, Alhejaili F, et al. Efficacy of vitamin D replacement therapy in restless legs syndrome: A randomized control trial. Sleep Breath. 2019; 23: 595–601. DOI: 10.1007/s11325-018-1751-2
    Back to article
  22. 22Tutuncu M, Tutuncu M. The effect of vitamin D on restless legs syndrome: Prospective self-controlled case study. Sleep Breath; 2020.
    Back to article
  23. 23King G, Petrenchik T, Dewit D, et al. Out-of-school time activity participation profiles of children with physical disabilities: A cluster analysis. Child Care Health Dev. 2010; 36: 726–41. DOI: 10.1111/j.1365-2214.2010.01089.x
    Back to article
  24. 24Shields N, Synnot A. Perceived barriers and facilitators to participation in physical activity for children with disability: A qualitative study. BMC Pediatr. 2016; 16: 9. DOI: 10.1186/s12887-016-0544-7
    Back to article
  25. 25Rath JJG, Deen MEJ, van Houten H, et al. Antipsychotic-induced hyperprolactinemia in Tourette syndrome. Ther Adv Psychopharmacol. 2017; 7: 201–205. DOI: 10.1177/2045125317705012
    Back to article
  26. 26Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis. J Psychopharmacol. 2012; 26: 42–51. DOI: 10.1177/0269881112442016
    Back to article
  27. 27Calarge CA, Ivins SD, Motyl KJ, et al. Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents. Ther Adv Psychopharmacol. 2013; 3: 278–93. DOI: 10.1177/2045125313487548
    Back to article
  28. 28Lu YY, Wang MY, Wei IH, et al. Tourette syndrome increases risk of bone fractures: A population-based cohort study. Eur Child Adolesc Psychiatry. 2017; 26: 531–539. DOI: 10.1007/s00787-016-0916-4
    Back to article
  29. 29Gemawat N. Vit-D and Tics Movement Disorder. Movement Disorders. 2017; 32: 1158.
    Back to article
  30. 30Sazci A, Uren N, Idrisoglu HA, et al. The rs2228570 Variant of the Vitamin D Receptor Gene is Associated with Essential Tremor. Neurosci Bull. 2019; 35: 362–364. DOI: 10.1007/s12264-018-0287-6
    Back to article
  31. 31Butler MW, Burt A, Edwards TL, et al. Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet. 2011; 75: 201–10. DOI: 10.1111/j.1469-1809.2010.00631.x
    Back to article
  32. 32Kato H, Kobayashi K, Kohari S, et al. Paroxysmal kinesigenic choreoathetosis and paroxysmal dystonic choreoathetosis in a patient with familial idiopathic hypoparathyroidism. Tohoku J Exp Med. 1987; 151: 233–9. DOI: 10.1620/tjem.151.233
    Back to article
  33. 33Mohanty S, Gulati U. Mandibular angle and coronoid process fracture secondary to orofacial dystonia: Report of a case. Int J Orofacial Myology. 2013; 39: 24–30.
    Back to article
  34. 34McDade E, Weiner WJ, Shulman LM. Metatarsal fracture as a consequence of foot dystonia in Parkinson’s disease. Parkinsonism Relat Disord. 2008; 14: 353–5. DOI: 10.1016/j.parkreldis.2007.07.005
    Back to article
  35. 35Boyce MJ, Lam L, Chang F, et al. Validation of Fear of Falling and Balance Confidence Assessment Scales in Persons With Dystonia. J Neurol Phys Ther. 2017; 41: 239–244. DOI: 10.1097/NPT.0000000000000198
    Back to article
  36. 36Habibi AH, Anamoradi A, Shahidi GA, et al. Treatment of Levodopainduced dyskinesia with Vitamin D: A Randomized, double-blind, placebo-controlled trial. Neurol Int. 2018; 10: 7737. DOI: 10.4081/ni.2018.7737
    Back to article
  37. 37Gardiol C, Lamy O, Humbert A. Myoclonia in an oldest old woman: A frequent and reversible etiology. Praxis. 2010; 99: 315–318. DOI: 10.1024/1661-8157/a000055
    Back to article
  38. 38Klein C, Gurvich N, Sena-Esteves M, et al. Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Ann Neurol. 2000; 47: 369–73. DOI: 10.1002/1531-8249(200003)47:3<;369::AID-ANA14>3.0.CO;2-9
    Back to article
  39. 39Gandhy RP, Shamim EA. Brainstem reticular myoclonus. In: Kompoliti K, Verhagen L (eds.), Encyclopedia of Movement Disoprders. 2010; 1: 165–166. Salt Lake City, UT, USA: Academic Press. DOI: 10.1016/B978-0-12-374105-9.00048-4
    Back to article
  40. 40Glass GA, Ahlskog JE, Matsumoto JY. Orthostatic myoclonus: A contributor to gait decline in selected elderly. Neurology. 2007; 68: 1826–30. DOI: 10.1212/01.wnl.0000260225.46732.af
    Back to article
  41. 41Kravietz A, Kab S, Wald L, et al. Association of UV radiation with Parkinson disease incidence: A nationwide French ecologic study. Environ Res. 2017; 154: 50–56. DOI: 10.1016/j.envres.2016.12.008
    Back to article
  42. 42Cui X, Pelekanos M, Liu PY, et al. The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience. 2013; 236: 77–87. DOI: 10.1016/j.neuroscience.2013.01.035
    Back to article
  43. 43Alfieri DF, Lehmann MF, Oliveira SR, et al. Vitamin D deficiency is associated with acute ischemic stroke, C-reactive protein, and short-term outcome. Metab Brain Dis. 2017; 32: 493–502. DOI: 10.1007/s11011-016-9939-2
    Back to article
  44. 44Chin K, Zhao D, Tibuakuu M, et al. Physical Activity, Vitamin D, and Incident Atherosclerotic Cardiovascular Disease in Whites and Blacks: The ARIC Study. J Clin Endocrinol Metab. 2017; 102: 1227–1236. DOI: 10.1210/jc.2016-3743
    Back to article
  45. 45Chaudhuri JR, Mridula KR, Alladi S, et al. Serum 25-hydroxyvitamin D deficiency in ischemic stroke and subtypes in Indian patients. J Stroke. 2014; 16: 44–50. DOI: 10.5853/jos.2014.16.1.44
    Back to article
  46. 46Poole KE, Loveridge N, Barker PJ, et al. Reduced vitamin D in acute stroke. Stroke. 2006; 37: 243–5. DOI: 10.1161/01.STR.0000195184.24297.c1
    Back to article
  47. 47Nieves J, Cosman F, Herbert J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994; 44: 1687–92. DOI: 10.1212/WNL.44.9.1687
    Back to article
  48. 48Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 2014; 108: 1352–6. DOI: 10.1016/j.eplepsyres.2014.06.008
    Back to article
  49. 49Shehab D, Al-Jarallah K, Mojiminiyi OA, et al. Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes? Diabet Med. 2012; 29: 43–9. DOI: 10.1111/j.1464-5491.2011.03510.x
    Back to article
  50. 50Camu W, Tremblier B, Plassot C, et al. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol Aging. 2014; 35: 1198–205. DOI: 10.1016/j.neurobiolaging.2013.11.005
    Back to article
  51. 51Allen NE, Schwarzel AK, Canning CG. Recurrent Falls in Parkinson’s Disease: A Systematic Review. Parkinson’s Disease. 2013; 2013: 16. DOI: 10.1155/2013/906274
    Back to article
  52. 52Bischoff-Ferrari HA, Borchers M, Gudat F, et al. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004; 19: 265–9. DOI: 10.1359/jbmr.2004.19.2.265
    Back to article
  53. 53Girgis CM, Clifton-Bligh RJ, Turner N, et al. Effects of vitamin D in skeletal muscle: Falls, strength, athletic performance and insulin sensitivity. Clin Endocrinol (Oxf). 2014; 80: 169–81. DOI: 10.1111/cen.12368
    Back to article
  54. 54Zhou Z, Zhou R, Zhang Z, et al. The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson’s Disease: A Systematic Review and Meta-Analysis. Medical science monitor: International medical journal of experimental and clinical research. 2019; 25: 666–674. DOI: 10.12659/MSM.912840
    Back to article
  55. 55Harms LR, Burne THJ, Eyles DW, et al. Vitamin D and the brain. Best Practice & Research Clinical Endocrinology & Metabolism. 2011; 25: 657–669. DOI: 10.1016/j.beem.2011.05.009
    Back to article
  56. 56Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002; 13: 100–5. DOI: 10.1016/S1043-2760(01)00547-1
    Back to article
  57. 57Goodsell DS. The molecular perspective: Cytochrome C and apoptosis. Stem Cells. 2004; 22: 428–9. DOI: 10.1634/stemcells.22-3-428
    Back to article
  58. 58Lương K, Nguyễn L. Role of vitamin D in Parkinson’s disease. ISRN neurology. 2012; 2012: 134289–134289. DOI: 10.5402/2012/134289
    Back to article
  59. 59Gezen-Ak D, Dursun E. Molecular basis of vitamin D action in neurodegeneration: The story of a team perspective. Hormones. 2019; 18: 17–21. DOI: 10.1007/s42000-018-0087-4
    Back to article
  60. 60Moretti R, Morelli ME, Caruso P. Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact. International journal of molecular sciences. 2018; 19: 2245. DOI: 10.3390/ijms19082245
    Back to article
  61. 61Ciaschini PM, Straus SE, Dolovich LR, et al. Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies. Trials. 2008; 9: 62. DOI: 10.1186/1745-6215-9-62
    Back to article
  62. 62Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: A meta-analysis of randomized controlled trials. Arch Intern Med. 2009; 169: 551–61. DOI: 10.1001/archinternmed.2008.600
    Back to article
DOI: https://doi.org/10.5334/tohm.74 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Apr 22, 2020
Accepted on: Jul 29, 2020
Published on: Aug 25, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Vitamin D,
movement disorders,
hyperkinetic movements,
fractures,
bone structure

© 2020 Carl N. Homann, Gerd Ivanic, Barbara Homann, Tadeja Urbanic Purkart, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 10 (2020): Issue 0Next article